Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sitaxsentan: Waiting for efficacy

It's too early to jump to conclusions about the meaning of the liver abnormalities seen in trials of sitaxsentan, an endothelin receptor antagonist being developed by Texas Biotechnology Corp. and partner Icos Corp. to treat pulmonary arterial hypertension (PAH). The side effect appears to be endemic to this class of compounds, and the

Read the full 538 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE